leisure time -WSS

leisure time

author：knowledge 2025-09-27 17:03:18 - browse：8

Novo Nordisk headquarters -- health coverage from STAT — Novo Nordisk's headquarters, outside Copenhagen, Denmark. LISELOTTE SABROE/Scanpix/AFP via Getty Images

Novo Nordisk is pausing ads for its obesity drug Wegovy as it struggles to keep up with surging demand, the latest hurdle in its rollout of the weight loss drug.

“To avoid stimulating further demand for this medicine, we’re pausing some key Wegovy promotional efforts,” the Danish drugmaker said in an emailed statement. “We are pausing all local television advertising and postponing planned national television advertising for Wegovy. We are also assessing our promotional efforts to healthcare professionals and adjusting accordingly.” The news was earlier reported by Endpoints.

Wegovy, which contains the active ingredient semaglutide, has become immensely popular for its effectiveness in helping people lose weight and is helping usher in what many see as a sea change in obesity treatment. Its sister drug for diabetes, Ozempic, has also been in demand for a similar effect on weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical records are filled with copy
Next article： FTC loses bid to block Novant's North Carolina hospital merger

WSS

UnitedHealth CEO's Medicaid comments send insurer stocks diving

Stopping antidepressants leads to symptoms for 1 in 6 patients

FTC loses bid to block Novant's North Carolina hospital merger

A new initiative will help leaders fight the next pandemic

Fight over Supreme Court dialysis ruling puts kidney patients at risk

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

hotspot

leisure time

hotspot

Jerome Adams on the need for new antivirals for Covid

Pfizer's RSV vaccine recommended for approval in Europe

Apple is now the first public company to be valued at $3 trillion

CMS got Medicare Advantage quality rating wrong, judge rules

Bright Health sells Medicare Advantage business to Molina

Biden White House, tech companies launch new safeguards around emerging AI technology

Duchenne breakthrough therapy leaves behind pioneering families

Prosecutors say FTX founder Sam Bankman

Sports medicine is finally prioritizing gender equality

Listen: BridgeBio's big week & Lilly's Alzheimer's data

leisure time

BD to buy Edwards patient monitoring unit for $4.2 billion

The biotech scorecard for the 2nd quarter: 12 industry events to watch

How CO2 helps viruses stay alive longer in the air

Dispute over threat of extinction posed by artificial intelligence looms over surging industry

CMS got Medicare Advantage quality rating wrong, judge rules

Finland to offer bird flu vaccine to select groups of people, a possible global first

hotspot

Wikipedia

focus

leisure time